Biacore: Year-End Report 2004

UPPSALA, Sweden, Feb. 17, 2005 (PRIMEZONE) -- Biacore: Year-End Report 2004

 - Strong sales in Europe and a recovery in Japan in the 
   fourth quarter all but compensated for a continuing weakness
   in the Americas. Total sales in the final quarter 2004 amounted
   to SEK 158.6 million (160.8). For the full-year 2004, sales
   were SEK 495.8 million (515.5), a decline of 4%. Excluding 
   currency effects, full-year sales increased by 4%.

 - Operating income for the fourth quarter amounted to SEK 14.3
   million (54.7) after non-recurring costs of SEK 32 million
   related to the successfully implemented turnaround program,
   defined in the Strategic Business Review. After total
   non-recurring costs of SEK 90 million, an operating loss
   of SEK 5.1 million (+29.5) was recorded for the full-year 2004.

 - Biacore is rapidly expanding its unique product portfolio
   for protein interaction analysis. The strategic roll-out of
   the array technology was initiated in late 2004, following
   a deal with AIST, a major Japanese research institute focused
   on proteomics. In early February 2005, the new Biacore(R)T100
   was launched at the Association of Biomolecular Resource
   Facilities (ABRF).

 - The progress that Biacore has made in the final months of
   2004 combined with an anticipated return to profitability in 2005
   has allowed the Board to propose an unchanged dividend of
   SEK 3.00 per share for 2004.

- In 2005, Biacore anticipates achieving an increase in sales
  and returning to historic levels of profitability with variations
  between the quarters being exaggerated by the launch of
  Biacore(R)T100 in the first quarter.

 For further information, please contact:

 Erik Wallden, President and CEO, Phone +41 (0)79 769 4542 
 Lars-Olov Forslund, CFO, Phone +41 (0)79 347 9900
 Jan Isoz, Investor Relations, Phone +46 (0)708 10 31 17

This information was brought to you by Waymaker

The following files are available for download: